[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Isfahan University of Medical Sciences\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":206},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,43,65,94,118,147,175],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100610641","phase-1-effect-of-evfv-on-wound-healing-in-dystrophic-epidermolysis-bullosa-100610641",false,"NCT07230223","Effect of Ev.FV on Wound Healing in Dystrophic Epidermolysis Bullosa","Safety and Efficacy of Ev.FV in Epidermolysis Bullosa Patients, A Randomized Clinical Trial, Phase 1 , 2","Inclusion Criteria:\n\n* DEB participants determined by electron microscopy, or genetic testing. Individuals with severe DEB (eg, RDEB patients with an absence of collagen VII) and milder forms of DEB (eg, RDEB patients with reduced levels of collagen VII) will be eligible.\n* People with one or more active wounds (each between 10 and 50 square centimeters on the arms, legs or trunk.)\n* Participants must be willing to comply with the requirements of the protocol and have consent to participate in the project.\n* Participants must be negative in the urine drug screening visit.\n\nExclusion Criteria:\n\n* Participants with clinical evidence of systemic infection.\n* Participants have a history of bone marrow transplantation.\n* Participants must have evidence of autoimmune disease, including insulin-dependent diabetes.\n* Participant has evidence of significant wound healing prior to treatment (ie, wound closure ≥ 20% during treatment at the first observation period).\n* Participant has a severe medical condition, such as malignancy (including skin cancer), life expectancy less than 2 years, which limits movement to the clinical center.\n* Participants have a current history of alcohol or substance abuse or a history of alcohol or substance abuse that requires treatment in the past 12 months.\n* People participating in the screening should have a positive hepatitis and human immunodeficiency virus (HIV) test result.\n* Women who are pregnant, lactating or planning to become pregnant during the study\n* Women who are of reproductive age and use birth control pills.","ALL","3 Years","35 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","Epidermolysis bullosa (EB) is a hereditary disease of skin tissues that causes painful bleeding blisters in the skin and mucous membrane. The prevalence of this disease is 1 in 50,000. The severity of the disease varies depending on the type of disease and may even lead to death. This disease is caused by a genetic mutation in keratin or collagen, and its incidence is the same in all men and women of different human races. In these patients, the skin becomes extremely fragile and peels off with the slightest scratch. Many blisters are one of the most obvious symptoms of this disease. The possibility of skin cancer in people suffering from this disease is more than others.\n\nNowadays, the preference of cell therapy methods is to use biological products produced by cells such as extracellular vesicles and mitochondria instead of stem cells. The use of Extracellular vesicles and engineered EVs as messenger carriers can introduce a new treatment method based on cell products for skin regeneration and as an alternative to cell therapy.\n\nTherefore, in this study, EV.FV will be applied topically to patients.",[28,29],"Dystrophic Epidermolysis Bullosa","Wound Heal","RECRUITING","2025-11-14",{"date":33,"type":34},"2025-11-17","ACTUAL",{"date":36,"type":34},"2024-01-09",{"date":38,"type":21},"2026-12-25",{"name":40,"class":41},"Isfahan University of Medical Sciences","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":64,"locationsCount":42},"100551958","mesenchymal-stem-cells-derived-exosomes-in-osteoarthritis-patients-100551958","NCT06466850","Mesenchymal Stem Cells Derived Exosomes in Osteoarthritis Patients","The Efficacy of Allogenic Mesenchymal Stem Cells Derived Exosomes in Osteoarthritis Patients","Inclusion Criteria:\n\n* Chronic history (for at least 3 months) of knee joint pain\n* Body mass index (BMI) between 21.5 and 29.5\n* Radiographically documented knee osteoarthritis of grades 1 to 3 (Kellgren-Lawrence (K-L) radiographic classification scale)\n\nExclusion Criteria:\n\n* Rheumatoid arthritis and other rheumatic diseases\n* Varus or valgus more than 10 degrees; lateral subluxation of the patella\n* Deformity at the joint levels or adjacent to the knee due to fracture or any other injury\n* Complete rupture of the ligament and meniscus leading to laxity or locking\n* Serious systemic, oncohematological, autoimmune diseases; history of severe allergy; serious failure of vital organs, inability to walk\n* Hyaluronic acid infiltration within the previous six months\n* Hemoglobin levels \\\u003C10 g\u002FdL;","45 Years","75 Years",{"count":20,"type":21},[54],"NA","Present research focuses on the potential of exosomes, which are small vesicles secreted by mesenchymal stem cells (MSCs), as a therapeutic approach for osteoarthritis (OA).\n\nOA is a degenerative joint disorder characterized by the destruction of cartilage and loss of extracellular matrix. It's associated with pro-inflammatory cytokines and increased expression of matrix metalloproteinase (MMP) and \"a disintegrin and metalloproteinase with thrombospondin motifs\" (ADAMTS).\n\nMSCs have been explored as a new treatment for OA over the last decade1. It's suggested that the paracrine secretion of trophic factors, in which exosomes play a crucial role, contributes to the mechanism of MSC-based treatment of OA.\n\nExosomes derived from MSCs may suppress OA development. They carry bioactive molecules of the parental cells, including non-coding RNAs (ncRNAs) and proteins and anti-inflammatory factors. These exosomes have shown a significant impact on the modulation of various physiological behaviors of cells in the joint cavity.\n\nThis research provides hope for developing more effective and predictable methods of using MSC-derived exosomes for OA treatment.",[57],"Osteoarthritis, Knee","2025-09-08",{"date":60,"type":34},"2025-09-15",{"date":62,"type":34},"2024-01-01",{"date":38,"type":21},{"name":40,"class":41},{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":72,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":22,"phases":75,"briefSummary":76,"conditions":77,"keywords":81,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":4},"100595400","3d-eye-movement-simulator-for-medical-education-100595400","NCT07031960","3D Eye Movement Simulator for Medical Education","Design, Construction and Evaluation of the Educational Effects of 3D Simulator of Human Eyeball Movements","Inclusion Criteria:\n\n1. Academic Status Currently enrolled medical students in their preclinical years (typically 2nd-3 year)\"\n2. Course Enrollment \"Formally registered in the special scence\u002Fanatomy course where eye movement education is part of the curriculum\"\n\nPrior Experience \"No previous formal training in extraocular muscle anatomy or eye movement assessment\"\n\nLanguage Proficiency \"Fluent in the language of instruction (Farsi)\"\n\nConsent \"Willing and able to provide informed consent\"\n\nExclusion Criteria:\n\n1- Prior Exposure \"Medical students who have previously taken advanced special scence courses\"\n\nProfessional Experience \"Students with prior clinical experience in ophthalmology ( as nurses or technicians)\"\n\nAtypical Curriculum \"Students from schools with non-standard anatomy curricula that already include similar 3D simulation tools\"\n\nParticipation Conflicts \"Currently participating in other educational research studies that could confound results\"",true,{"count":74,"type":21},76,[54],"The goal of this clinical trial is to evaluate whether a new 3D-printed eyeball movement simulator improves medical education compared to traditional teaching methods. The main questions it aims to answer are:\n\nDoes using the 3D simulator help medical students better understand eye anatomy and muscle function compared to standard lectures and textbooks?\n\nHow do students rate the usability and effectiveness of this new teaching tool?\n\nResearchers will compare two groups of medical students:\n\nOne group will learn using the 3D simulator\n\nThe other group will receive standard teaching methods\n\nParticipants will:\n\n1. Complete a pre-test to assess their baseline knowledge\n2. Attend training sessions using either the 3D simulator or standard methods\n3. Take a post-test to measure learning improvement\n4. Provide feedback about their learning experience\n5. Take a post-intervention exam and satisfaction survey\n6. Participate in focus groups about their learning experience\n\nThe study will help determine if interactive 3D models can enhance medical education about eye movements.",[78,79,80],"Education","Education, Medical, Undergraduate","Education, Medical",[82,83,84],"medical education","3D model","eye movement","NOT_YET_RECRUITING","2025-06-19",{"date":88,"type":34},"2025-06-22",{"date":90,"type":21},"2025-06-15",{"date":92,"type":21},"2025-08-20",{"name":40,"class":41},{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":72,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":22,"phases":103,"briefSummary":104,"conditions":105,"keywords":106,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":4},"100592323","construction-and-educational-impact-of-plastination-models-of-the-limbic-system-basal-nuclei-cerebellum-and-human-spinal-cord-100592323","NCT06991933","Construction and Educational Impact of Plastination Models of the Limbic System, Basal Nuclei, Cerebellum, and Human Spinal Cord","Preparation and Construction of Volumetric Plastination Models of the Limbic System, Basal Nuclei, Cerebellum, and Human Spinal Cord and Evaluation of Their Educational Effects","Inclusion Criteria:\n\n* Medical students in their third semester of training\n* Currently enrolled in neuroanatomy coursework at Isfahan University of Medical Sciences\n* No prior formal training with plastinated models\n* Willing to attend all study sessions for 7 weeks\n* Able to complete assessments in persian\n\nExclusion Criteria:\n\n* Prior experience with plastinated models\n* Currently taking neuroanatomy remediation courses\n* Planned absences during \\>20% of study sessions",{"count":102,"type":21},60,[54],"Purpose:\n\nThis educational trial aims to assess whether plastination models for neuroanatomy training (limbic system, basal ganglia, cerebellum, spinal cord)\" improve medical students' understanding of central nervous system anatomy compared to traditional educational methods. It will also evaluate student satisfaction with this teaching tool.\n\nKey Questions:\n\n1. Do plastination models for neuroanatomy training (limbic system, basal ganglia, cerebellum, spinal cord) enhance test scores in neuroanatomy examinations?\n2. How do students perceive the educational value of these models?\n\nStudy Design:\n\nResearchers will compare two teaching methods:\n\n* Intervention group: Learns using plastination models for neuroanatomy training (limbic system, basal ganglia, cerebellum, spinal cord)\n* Control group: Learns using standard 2D atlases, power point and plastic models\n\nParticipants will:\n\n1. Complete a pre-intervention anatomy knowledge test\n2. Attend 4 weekly neuroanatomy sessions using their assigned method\n3. Take a post-intervention exam and satisfaction survey\n4. Participate in focus groups about their learning experience",[78,80,79],[107,108,109],"Medical education","Neuroanatomy","plastination model","2025-05-26",{"date":112,"type":34},"2025-05-28",{"date":114,"type":21},"2025-10-23",{"date":116,"type":21},"2026-01-20",{"name":40,"class":41},{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":16,"minAge":125,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":22,"phases":129,"briefSummary":130,"conditions":131,"keywords":133,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":42},"100591295","comparative-efficacy-of-adm-hydrogel-vs-alginate-dressings-in-chronic-trauma-wounds-100591295","NCT06978569","Comparative Efficacy of ADM Hydrogel vs. Alginate Dressings in Chronic Trauma Wounds","A Randomized, Outcome Assessor-Blinded Clinical Trial Comparing the Efficacy of Acellular Dermal Matrix (ADM) Hydrogel Versus Alginate Dressings in the Treatment of Chronic Traumatic Wounds","Inclusion Criteria:\n\n* Chronic trauma wounds persisting ≥3 weeks.\n* Wound size between 4 and 20 cm² and depth ≤9 mm on the lower limbs.\n* Willingness and ability to provide informed consent.\n* Wounds without uncontrolled infection\n\nExclusion Criteria:\n\n* Wounds with exposed bone.\n* Current use of immunomodulators, corticosteroids, immunosuppressive or cytotoxic drugs.\n* Pregnant individuals.\n* Significant reduction (≥30%) of wound size during a 2-week run-in phase.\n* Concurrent participation in another clinical trial involving drugs.\n* Wounds with uncontrolled infection\n* Allergy or hypersensitivity to components of ADM gel or alginate","18 Years","65 Years",{"count":128,"type":21},130,[54],"The goal of this clinical trial is to find out whether a wound treatment made from acellular dermal matrix (ADM) gel can help heal chronic traumatic wounds more effectively than standard alginate dressings in adults aged 18 and older with wounds that have lasted more than 3 weeks.\n\nThe main questions it aims to answer are:\n\nDoes ADM gel reduce the size of chronic wounds more than alginate dressings after 12 weeks?\n\nDoes ADM gel help wounds heal faster and improve quality of life for patients?\n\nResearchers will compare ADM gel to alginate dressings to see if the ADM gel leads to better healing results and fewer complications.\n\nParticipants will:\n\nBe randomly assigned to receive either ADM gel or alginate dressing.\n\nHave the treatment applied directly to their cleaned wound.\n\nAttend weekly visits for up to 12 weeks for wound checks, measurements, and dressing changes.",[132],"Trauma Wounds",[134,135,136,137,138],"chronic wound","acellular dermal matrix","ADM","wound size","alginate","2025-05-11",{"date":141,"type":34},"2025-05-18",{"date":143,"type":21},"2025-07",{"date":145,"type":21},"2026-09",{"name":40,"class":41},{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":154,"minAge":125,"maxAge":50,"enrollmentInfo":155,"targetDuration":4,"studyType":22,"phases":157,"briefSummary":158,"conditions":159,"keywords":162,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":42},"100565452","phase-1-the-effectiveness-of-astaxanthin-supplementation-on-the-clinical-symptoms-and-cardio-metabolic-profile-in-women-with-polycystic-ovary-syndrome-100565452","NCT06642363","The Effectiveness of Astaxanthin Supplementation on the Clinical Symptoms and Cardio-metabolic Profile in Women with Polycystic Ovary Syndrome","The Effectiveness of Astaxanthin Supplementation on the Clinical Symptoms and Cardio-metabolic Profile in Women with Polycystic Ovary Syndrome: a Protocol for a Randomized Double-blinded, Placebo-controlled Parallel-group Study","Inclusion Criteria:\n\n1. Age 18 - 45 years\n2. Clinical diagnosis of polycystic ovary syndrome\n3. Have a body mass index of 25-35 kg\u002Fm 2\n4. Absence of pregnancy and breastfeeding\n5. No intake of medicine\n6. Not willing to get pregnant during the study\n7. No presence of chronic inflammatory diseases or other endocrine disorders\n8. No current treatments except metformin\n9. No intake of dietary supplements within at last 2 previous months\n\nExclusion Criteria:\n\n1. Consuming less than 80% of the total administered ASX supplements\n2. Ongoing pregnancy\n3. Changing their usual diet or eating habits or level of physical activity\n4. Presence of Skin or digestive allergy symptoms or any desired complications by intake of ASX supplementation\n5. Smoking or alcohol consumption","FEMALE",{"count":156,"type":21},44,[24],"Abstract Background: This trial aims to investigate the effect of 12 weeks of 10 mg\u002Fday astaxanthin (ASX) administration compared with the control group on insulin sensitivity, lipid profile, circulating MDA levels, severity of hirsutism, and depression in women with Polycystic Ovary Syndrome (PCOS).\n\nMethods: This manuscript will outline the design, methodology, and potential clinical implications of ASX supplementation in eligible women with PCOS and a body mass index of 25-35 kg\u002Fm2, who are referred to the gynecologist clinic in Isfahan, Iran, during 2024-2025.\n\nDiscussion: This study is one of the first attempts to assess the clinical efficacy of astaxanthin as an auxiliary treatment in PCOS patients, and will provide more evidence in this area.\n\nTrial registration number: Iran Clinical Trials (IRCT) website. (IRCT20231001059573N1)",[160,161],"PCO - Polycystic Ovaries","Obesity and Obesity-related Medical Conditions",[163,164,165,166],"Astaxanthin","Polycystic Ovary Syndrome","Obesity","Hirsutism","2024-10-15",{"date":169,"type":34},"2024-10-17",{"date":171,"type":34},"2024-07-22",{"date":173,"type":21},"2025-07-22",{"name":40,"class":41},{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":16,"minAge":182,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":22,"phases":185,"briefSummary":187,"conditions":188,"keywords":192,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":42},"100561837","phase-2-efficacy-and-safety-of-intravitreal-injection-of-bevacizumab-with-and-without-oral-curcumin-100561837","NCT06595355","Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral Curcumin","Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral Curcumin in Diabetic Macular Edema","Inclusion Criteria:\n\nPatients with center-involving macular edema with macular center thickness more than 300 microns in OCT 2-Patients who did not receive intravitreal bevacizumab in the last 3 months and intravitreal corticosteroids in the last 6 months.\n\n3- The amount of BCVA should not be \\\u003C20\u002F400. 4-Consent to participate in the study\n\nExclusion Criteria:\n\n1. Other retinal diseases except for DME and macular edema due to other causes including uveitis, epiretinal membrane, central retinal vein occlusion, and...\n2. Existence of proliferative diabetic retinopathy and patients with a history of vitrectomy\n3. Patients with glaucoma, vitreous hemorrhage, age-related macular degeneration (ARMD)\n4. Media opacities that limit the interpretation of diagnostic tests\n5. Surgery or procedure 3 months before starting treatment\n6. Pregnancy or breastfeeding\n7. History of allergy to curcumin\n8. Use of warfarin\n9. Changing the patient's clinical diagnosis or the need for surgical interventions in the course of the disease\n10. Change in the patient's general health condition\n11. Absence of patient referrals\n12. Lack of consent to continue treatment and follow-up","40 Years",{"count":184,"type":21},52,[25,186],"PHASE3","The purpose of this study is to evaluate the effectiveness of adding curcumin oral treatment to bevacizumab intravitreal injection in patients with central macular edema.\n\nA blind study and a randomized and controlled clinical trial are conducted on diabetic patients with macular edema. The patients are divided into two intervention groups (bevacizumab + curcumin) and control (bevacizumab + placebo).\n\nThe evaluation of the central thickness of the macula and the evaluation of the central volume of the macula are the primary goals and the evaluation of the best visual acuity of the patient is the secondary goal.",[189,190,191],"Diabetic Macular Edema","Macular Edema","Retinal Neovascularization",[193,194,195,196,197,191],"macular edema","diabetic macular edema","central macular edema","bevacizumab","Diabetic Retinopathy","2024-09-10",{"date":200,"type":34},"2024-09-19",{"date":202,"type":34},"2021-10-10",{"date":204,"type":21},"2025-09-22",{"name":40,"class":41},""]